Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well pazopanib hydrochloride works in treating patients with
advanced neuroendocrine cancer. Pazopanib hydrochloride may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.